Taking nature’s lead
in antimicrobials

NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
23-Nov-2017

Enrolment reaches 50% in Lynovex CARE-CF-1 trial
02-Nov-2017

NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Indianapolis
30-Oct-2017

Reflections from World AMR Congress
19-Oct-2017

EuropaBio announces the finalists for the Most innovative European Biotech SME Awards 2017
18-Oct-2017

NovaBiotics at World Antimicrobial Resistance Congress, Washington
13-Sep-2017

NovaBiotics at ASM/ESCMID Conference
31-Aug-2017

NovaBiotics at the 7th International Meeting on Antimicrobial Peptides
21-Aug-2017

NovaBiotics Chief Executive responds to Public Health England warning on Candida auris fungus
16-Aug-2017

City doctor at the heart of a global superbug battle
04-Aug-2017

NovaBiotics featured on STV News
04-Aug-2017

New Drug Kills MRSA – including strains with antibiotic resistance
03-Aug-2017

50th patient recruited for CARE- CF-1 Lynovex clinical study
01-Aug-2017

NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16-Jun-2017

NovaBiotics participating in BIO 2017 in San Diego
15-Jun-2017

NovaBiotics at European Cystic Fibrosis Conference in Seville
06-Jun-2017

NovaBiotics at American Society for Microbiology
26-May-2017

30 subjects now randomised in Lynovex CARE-CF-1 trial
10-May-2017

NovaBiotics contribution to ECCMID 2017
13-Apr-2017

NovaBiotics Quality Management System Achieves ISO 9001 certification
11-Apr-2017

NovaBiotics to host live Twitter Lynovex Q&A
24-Mar-2017

NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21-Mar-2017

NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17-Mar-2017

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03-Mar-2017

NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21-Feb-2017

NovaBiotics at ECCMID 2017
25-Jan-2017

NovaBiotics CEO featured as one of 15 women leading in European Biotech
18-Jan-2017

NovaBiotics announces first patients dosed in Lynovex clinical study
16-Jan-2017

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. Novexatin and Novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform.  Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform.